Wierzbicki AS - Search Results

1

Time to look beyond just lowering the serum concentration of low density lipoprotein--high density lipoprotein levels are also important.

Nair DR, Wierzbicki AS, Mikhailidis DP. Nair DR, et al. Among authors: wierzbicki as. J R Soc Promot Health. 2001 Jun;121(2):98-101. doi: 10.1177/146642400112100210. J R Soc Promot Health. 2001. PMID: 11467215 Review.

2

HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin.

Mikhailidis DP, Wierzbicki AS. Mikhailidis DP, et al. Among authors: wierzbicki as. Curr Med Res Opin. 2000;16(2):139-46. Curr Med Res Opin. 2000. PMID: 10893658 Review.

3

Attaining United States and European guideline LDL-C levels with simvastatin in patients with coronary heart disease (the GOALLS study).

Mikhailidis DP, Wierzbicki AS. Mikhailidis DP, et al. Among authors: wierzbicki as. Curr Med Res Opin. 2000;16(3):205-7. Curr Med Res Opin. 2000. PMID: 11191011 No abstract available.

4

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel.

Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, Hamilton G, Monkman D, Patel V, Pittard J, Schachter M. Mikhailidis DP, et al. Among authors: wierzbicki as. Curr Med Res Opin. 2005 Jun;21(6):959-69. doi: 10.1185/030079905x48447. Curr Med Res Opin. 2005. PMID: 15969896

5

Natural statins and stroke.

Wierzbicki AS, Crook MA, Mikhailidis DP, Winder AF. Wierzbicki AS, et al. Circulation. 2000 Jan 25;101(3):E45. doi: 10.1161/01.cir.101.3.e45. Circulation. 2000. PMID: 10645940 No abstract available.

6

Statin-fibrate combination: therapy for hyperlipidemia: a review.

Wierzbicki AS, Mikhailidis DP, Wray R, Schacter M, Cramb R, Simpson WG, Byrne CB. Wierzbicki AS, et al. Curr Med Res Opin. 2003;19(3):155-68. doi: 10.1185/030079903125001668. Curr Med Res Opin. 2003. PMID: 12814127 Review.

7

Drug treatment of combined hyperlipidemia.

Wierzbicki AS, Mikhailidis DP, Wray R. Wierzbicki AS, et al. Am J Cardiovasc Drugs. 2001;1(5):327-36. doi: 10.2165/00129784-200101050-00003. Am J Cardiovasc Drugs. 2001. PMID: 14728015 Review.

8

More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia.

Wierzbicki AS, Crook MA, Nair DR, Mikhailidis DP, Winder AF. Wierzbicki AS, et al. Atherosclerosis. 2000 Jan;148(1):204. doi: 10.1016/s0021-9150(99)00360-3. Atherosclerosis. 2000. PMID: 10644290 No abstract available.

9

Targeting triglycerides in secondary prevention: should we bother?

Athyros VG, Kakafika AI, Wierzbicki AS, Karagiannis A, Mikhailidis DP. Athyros VG, et al. Among authors: wierzbicki as. Int J Clin Pract. 2009 Jan;63(1):15-8. doi: 10.1111/j.1742-1241.2008.01837.x. Int J Clin Pract. 2009. PMID: 19125988 Review. No abstract available.

10

Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidaemia of adult growth hormone deficiency.

Cummings MH, Christ E, Umpleby AM, Albany E, Wierzbicki A, Lumb PJ, Sönksen PH, Russell-Jones DL. Cummings MH, et al. J Clin Endocrinol Metab. 1997 Jun;82(6):2010-3. J Clin Endocrinol Metab. 1997. PMID: 9177423

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page